Experienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval
Shareholders should contact the firm as there may be limited time to enforce your rights.
Shareholders should contact the firm as there may be limited time to enforce your rights.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
MILWAUKEE , Dec. 15, 2025 /PRNewswire/ -- The Ademi Firm is investigating Generation Bio (Nasdaq: GBIO) for possible breaches of fiduciary duty and other violations of law in its recently announced...
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna - - Generation Bio’s cell-targeted lipid nanoparticles (ctLNP)...
CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), a biotechnology company, today reported third quarter financial results. Third Quarter 2025 Financial Results...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey Jonas...
• Geoff McDonough, MD to step down as CEO & President and become Chair of the Company’s Board of Directors • Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President ...